Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Expert Opinion on Biological Therapy

• Publication date

  2012-04-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14712598.2012.672968PMID 22471247
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights.

  2012cited by this paper
• Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies.

  2012cited by this paper
• Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study.

  2012cited by this paper
• Dose-finding study of peginesatide for anemia correction in chronic kidney disease patients.

  2011cited by this paper
• Acceptable changes in quality attributes of glycosylated biopharmaceuticals

  2011cited by this paper
• Biosimilars—why terminology matters

  2011influential reference
• Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation

  2011cited by this paper
• Pure Red Cell Aplasia Induced Only by Intravenous Administration of Recombinant Human Erythropoietin

  2011cited by this paper
• Biosimilar recombinant human erythropoietin induces the production of neutralizing antibodies.

  2011cited by this paper
• Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity

  2011cited by this paper
• Biosimilar agents in oncology/haematology: from approval to practice

  2011cited by this paper
• Developing the nation's biosimilars program.

  2011cited by this paper
• Absence of functional EpoR expression in human tumor cell lines.

  2010cited by this paper
• Quantification of the preexisting CD4 T-cell repertoire specific for human erythropoietin reveals its immunogenicity potential.

  2010cited by this paper
• ENGLISH ONLY FINAL EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 19 to 23 October 2009 GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS (SBPs)

  2010cited by this paper
• Clinical comparability and European biosimilar regulations

  2010cited by this paper
• Biosimilar epoetins and other “follow‐on” biologics: Update on the European experiences

  2010cited by this paper
• Immunological mechanism underlying the immune response to recombinant human protein therapeutics.

  2010cited by this paper
• Therapeutic Manipulation of the HIF Hydroxylases

  2010cited by this paper
• Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes

  2010cited by this paper
• Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD.

  2010cited by this paper
• A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia.

  2010cited by this paper
• Quality of Original and Biosimilar Epoetin Products

  2010cited by this paper
• Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body

  2010cited by this paper
• Pharmacokinetic and pharmacodynamic comparison of two recombinant human erythropoietin formulations after single subcutaneous administration: an open-label, sequence-randomized, two-treatment crossover study in healthy Korean male volunteers.

  2010cited by this paper
• Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia

  2010cited by this paper
• American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.

  2010cited by this paper
• Efficacy of recombinant erythropoietins: is there unity of international units?

  2009cited by this paper
• Physical and biophysical effects of polysorbate 20 and 80 on darbepoetin alfa.

  2009cited by this paper
• Erythropoietin in cancer patients.

  2009cited by this paper
• Therapeutic effects of epoetin zeta in the treatment of chemotherapy-induced anaemia

  2009cited by this paper
• Can we prevent immunogenicity of human protein drugs?

  2009cited by this paper
• Precipitation of a monoclonal antibody by soluble tungsten.

  2009cited by this paper
• Assessing the bioequivalence of biosimilars The Retacrit case.

  2009cited by this paper
• Tungsten-induced protein aggregation: solution behavior.

  2009cited by this paper
• Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease

  2009cited by this paper
• HX575, Recombinant Human Epoetin Alfa, for the Treatment of Chemotherapy-Associated Symptomatic Anaemia in Patients with Solid Tumours

  2009cited by this paper
• Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia.

  2009cited by this paper
• CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools.

  2009cited by this paper
• Emerging trends in plasma‐free manufacturing of recombinant protein therapeutics expressed in mammalian cells

  2009cited by this paper
• Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.

  2009cited by this paper
• Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial

  2009cited by this paper
• A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia.

  2009cited by this paper
• Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen.

  2009cited by this paper
• The association of anti-r-HuEpo-associated pure red cell aplasia with HLA-DRB1*09-DQB1*0309.

  2009cited by this paper
• The significance of glycosylation analysis in development of biopharmaceuticals.

  2009cited by this paper
• Current and upcoming erythropoiesis-stimulating agents, iron products, and other novel anemia medications.

  2009cited by this paper
• Pure red cell aplasia due to follow-on epoetin.

  2008cited by this paper
• Comparison of the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anaemia

  2008cited by this paper
• Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment

  2008cited by this paper
• Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells

  2008cited by this paper
• How to predict and prevent the immunogenicity of therapeutic proteins.

  2008cited by this paper
• Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia

  2008cited by this paper
• Pharmacy and pharmacology of biosimilars

  2008cited by this paper
• The challenge of biosimilars.

  2008cited by this paper
• Comparison of the therapeutic effects of epoetin zeta and epoetin alpha in the correction of renal anaemia.

  2008cited by this paper
• Bioequivalence of HX575 (Recombinant Human Epoetin Alfa) and a Comparator Epoetin Alfa after Multiple Subcutaneous Administrations

  2008cited by this paper
• The erythropoietin receptor in normal and cancer tissues.

  2008cited by this paper
• Biosimilars and biopharmaceuticals: what the nephrologists need to know--a position paper by the ERA-EDTA Council.

  2008cited by this paper
• A Phase I, Single and Fractionated, Ascending‐Dose Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of an Erythropoietin Mimetic Antibody Fusion Protein (CNTO 528) in Healthy Male Subjects

  2008cited by this paper
• HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques.

  2007cited by this paper
• Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis

  2007cited by this paper
• Recombinant EPO production--points the nephrologist should know.

  2007cited by this paper
• Comparative Erythropoietin Receptor Binding Kinetics of C.E.R.A. and Epoetin-β Determined by Surface Plasmon Resonance and Competition Binding Assay

  2007cited by this paper
• Erythropoietin after a century of research: younger than ever

  2007cited by this paper
• Lack of functional erythropoietin receptors of cancer cell lines

  2007cited by this paper
• Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-alpha hydroxylases.

  2007cited by this paper
• Effects of protein aggregates: An immunologic perspective

  2006cited by this paper
• Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.

  2006cited by this paper
• Anti-Epo receptor antibodies do not predict Epo receptor expression.

  2006cited by this paper
• Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in primary SPK transplantation: 3-year results of the Euro-SPK 001 trial.

  2005cited by this paper
• Erythropoietin‐induced, antibody‐mediated pure red cell aplasia *

  2005cited by this paper
• Two cases of pure red-cell aplasia due to anti-erythropoietin antibodies.

  2005cited by this paper
• Human erythropoietin gene therapy for patients with chronic renal failure.

  2005cited by this paper
• Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: A parallel, randomized, double blind study

  2005cited by this paper
• What is antibody-mediated pure red cell aplasia (PRCA)?

  2005cited by this paper
• Antibodies against Erythropoietin and Other Protein‐Based Therapeutics: An Overview

  2005cited by this paper
• Interaction of Polysorbate 80 with Erythropoietin: A Case Study in Protein–Surfactant Interactions

  2005cited by this paper
• Current Methods for Detecting Antibodies against Erythropoietin and Other Recombinant Proteins

  2005cited by this paper
• The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes.

  2005cited by this paper
• Evaluation of Methods to Detect and Characterize Antibodies against Recombinant Human Erythropoietin

  2004cited by this paper
• Pure red-cell aplasia and epoetin therapy.

  2004cited by this paper
• Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

  2004cited by this paper
• Activity evaluation and characterization of recombinant human erythropoietin in pharmaceutical products

  2003cited by this paper
• Micelle-Associated Protein in Epoetin Formulations: A Risk Factor for Immunogenicity?

  2003cited by this paper
• artigo original Avaliação da Atividade e Caracterização de Eritropoietina Humana Recombinante em Produtos Farmacêuticos

  2003cited by this paper
• Enhancement of therapeutic protein in vivo activities through glycoengineering

  2003cited by this paper
• Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.

  2002cited by this paper
• Bioequivalence and the immunogenicity of biopharmaceuticals

  2002cited by this paper
• Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin.

  2001cited by this paper
• Human immune response to recombinant human proteins.

  2001influential reference
• Development and characterization of novel erythropoiesis stimulating protein (NESP)

  2001cited by this paper
• Novel erythropoiesis stimulating protein.

  2000cited by this paper
• Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties.

  1998cited by this paper
• Identification and structural characterization of a mannose‐6‐phosphate containing oligomannosidic N‐glycan from human erythropoietin secreted by recombinant BHK‐21 cells

  1995cited by this paper

• The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions.

  2021cites this paper
• ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE

  2020cites this paper
• Sialic Acids Content Analysis of the Innovator and Biosimilar Darbepoetin Alfa by Fluorometric HPLC Assay

  2019cites this paper
• HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics

  2018cites this paper
• Protein heterogeneity and the immunogenicity of biotherapeutics.

  2018cites this paper
• Erythropoietin as a performance-enhancing drug: Its mechanistic basis, detection, and potential adverse effects.

  2017cites this paper
• Biologics: structural heterogeneity and immunogenicity.

  2017cites this paper
• Ten years of clinical experience with biosimilar human growth hormone: a review of safety data

  2017cites this paper
• University of Birmingham Posttranslational Modifications and the Immunogenicity of Biotherapeutics

  2016cites this paper
• Clinical trials for authorized biosimilars in the European Union: a systematic review

  2016cites this paper
• Hematopoietic growth factors in lung cancer

  2016cites this paper
• Posttranslational Modifications and the Immunogenicity of Biotherapeutics

  2016cites this paper
• Investigational therapies for renal disease-induced anemia

  2016cites this paper
• Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products.

  2016cites this paper
• Chapter 24 – Performance Enhancing Hormones in Sports Doping

  2016cites this paper
• Therapeutic efficacy of a biosimilar epoetin alfa in hemodialysis patients.

  2015cites this paper
• Performance Enhancing Hormone Doping in Sport

  2015cites this paper
• Cost-effectiveness of continuous erythropoietin receptor activator in anemia

  2014cites this paper
• Impact of anemia management with EPO on psychologic distress in cancer patients: results of a multicenter patient survey.

  2014cites this paper
• Optimal care of the infant, child, and adolescent on dialysis: 2014 update.

  2014cites this paper
• A QUM partnership approach to regulating biosimilars in Australia

  2014cites this paper
• Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease

  2014cites this paper
• Analytical approaches for the detection of emerging therapeutics and non-approved drugs in human doping controls.

  2014cites this paper
• Recombinant human erythropoietin and its analogues

  2013cites this paper
• Chemical and Genetic Modification

  2013cites this paper
• Safety of off-label erythropoiesis stimulating agents in critically ill patients: a meta-analysis

  2013cites this paper
• Anemia treatment in patients with chronic kidney disease.

  2013cites this paper
• Blood manipulation: current challenges from an anti-doping perspective.

  2013cites this paper
• Therapeutic approaches for lysosomal storage diseases: a patent update.

  2013cites this paper
• Renal Transporters and Biomarkers in Safety Assessment

  2013cites this paper
• Clinicoeconomics and Outcomes Research Dovepress

  year unknowncites this paper